Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine

Elias Jabbour; Hagop Kantarjian; Susan O'Brien; Tapan Kadia; Asifa Malik; Mary Alma Welch; Angela Teng; Jorge Cortes; Farhad Ravandi; Guillermo Garcia-Manero

doi:10.1016/j.clml.2013.05.004

Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine

Elias Jabbour, Hagop Kantarjian, Susan O'Brien, Tapan Kadia, Asifa Malik, Mary Alma Welch, Angela Teng, Jorge Cortes, Farhad Ravandi, Guillermo Garcia-Manero

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Background: After the World Health Organization (WHO) changed the definition of acute myeloid leukemia (AML) to ≥ 20% blasts, the International Working Group (IWG) response criteria for myelodysplasia were updated. This retrospective analysis evaluated response to decitabine using updated IWG criteria in patients pooled from 2 decitabine trials. Patients and Methods: Outcomes for patients with myelodysplastic syndrome (MDS) with baseline marrow blasts ≥ 20% and < 30% (RAEB-t group) and < 20% (MDS group) were compared. Results: Patients with RAEB-t (n = 26) had a significantly shorter time from diagnosis to study treatment (7.3 vs. 18.3 months), a higher International Prognostic Scoring System (IPSS) risk (77% vs. 16% high-risk patients), and lower median baseline platelet count (62.3 vs. 112.7 × 10³/μL) vs. patients with MDS (n = 157), yet no significant difference in overall response rate (ORR) (15.4% vs. 28.0%). Patients with MDS had better duration of response (9.9 vs. 5 months; P =.024) and overall survival (OS) (16.6 vs. 9.0 months; P =.021) compared with patients with RAEB-t. Conclusion: Decitabine is active in and may benefit patients with > 20% blasts (RAEB-t).

Original language	English (US)
Pages (from-to)	592-596
Number of pages	5
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	13
Issue number	5
DOIs	https://doi.org/10.1016/j.clml.2013.05.004
State	Published - Oct 2013
Externally published	Yes

Keywords

Acute myeloid leukemia
FAB classification
Myelodysplastic syndrome
RAEB-t
Survival

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.clml.2013.05.004

Cite this

Jabbour, E., Kantarjian, H., O'Brien, S., Kadia, T., Malik, A., Welch, M. A., Teng, A., Cortes, J., Ravandi, F., & Garcia-Manero, G. (2013). Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine. Clinical Lymphoma, Myeloma and Leukemia, 13(5), 592-596. https://doi.org/10.1016/j.clml.2013.05.004

Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine. / Jabbour, Elias; Kantarjian, Hagop; O'Brien, Susan et al.
In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 13, No. 5, 10.2013, p. 592-596.

Research output: Contribution to journal › Article › peer-review

Jabbour, E, Kantarjian, H, O'Brien, S, Kadia, T, Malik, A, Welch, MA, Teng, A, Cortes, J, Ravandi, F & Garcia-Manero, G 2013, 'Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine', Clinical Lymphoma, Myeloma and Leukemia, vol. 13, no. 5, pp. 592-596. https://doi.org/10.1016/j.clml.2013.05.004

@article{abd3564db0084ad6a20ef673aa81c608,

title = "Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine",

abstract = "Background: After the World Health Organization (WHO) changed the definition of acute myeloid leukemia (AML) to ≥ 20% blasts, the International Working Group (IWG) response criteria for myelodysplasia were updated. This retrospective analysis evaluated response to decitabine using updated IWG criteria in patients pooled from 2 decitabine trials. Patients and Methods: Outcomes for patients with myelodysplastic syndrome (MDS) with baseline marrow blasts ≥ 20% and < 30% (RAEB-t group) and < 20% (MDS group) were compared. Results: Patients with RAEB-t (n = 26) had a significantly shorter time from diagnosis to study treatment (7.3 vs. 18.3 months), a higher International Prognostic Scoring System (IPSS) risk (77% vs. 16% high-risk patients), and lower median baseline platelet count (62.3 vs. 112.7 × 103/μL) vs. patients with MDS (n = 157), yet no significant difference in overall response rate (ORR) (15.4% vs. 28.0%). Patients with MDS had better duration of response (9.9 vs. 5 months; P =.024) and overall survival (OS) (16.6 vs. 9.0 months; P =.021) compared with patients with RAEB-t. Conclusion: Decitabine is active in and may benefit patients with > 20% blasts (RAEB-t).",

keywords = "Acute myeloid leukemia, FAB classification, Myelodysplastic syndrome, RAEB-t, Survival",

author = "Elias Jabbour and Hagop Kantarjian and Susan O'Brien and Tapan Kadia and Asifa Malik and Welch, {Mary Alma} and Angela Teng and Jorge Cortes and Farhad Ravandi and Guillermo Garcia-Manero",

note = "Funding Information: This study was supported by research funding from Eisai Inc . Medical writing, editing, and graphics assistance were provided by Peloton Advantage and were funded by Eisai Inc. Funding Information: H.K. has received research grants from Eisai Inc. T.K. has received research grants from GlaxoSmithKline . A.T. is an employee of Eisai Inc. J.C. has served on a speaker's bureau and has received honoraria and research grants from Ariad , Bristol-Myers Squibb , Chemgenex , and Novartis . F.R. has served as a remunerated consultant for Sunesis and Genzyme, has received honoraria from Bristol-Myers Squibb, Celgene, Genzyme, Novartis, and Sunesis, and has received research grants from Bristol-Myers Squibb, Bayer-Onyx, Celgene, EMD Serono, Incyte, Merck, Serono, and Sanofi. All other authors have stated that they have no conflicts of interest. ",

year = "2013",

month = oct,

doi = "10.1016/j.clml.2013.05.004",

language = "English (US)",

volume = "13",

pages = "592--596",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Cancer Media Group",

number = "5",

}

TY - JOUR

T1 - Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine

AU - Jabbour, Elias

AU - Kantarjian, Hagop

AU - O'Brien, Susan

AU - Kadia, Tapan

AU - Malik, Asifa

AU - Welch, Mary Alma

AU - Teng, Angela

AU - Cortes, Jorge

AU - Ravandi, Farhad

AU - Garcia-Manero, Guillermo

N1 - Funding Information: This study was supported by research funding from Eisai Inc . Medical writing, editing, and graphics assistance were provided by Peloton Advantage and were funded by Eisai Inc. Funding Information: H.K. has received research grants from Eisai Inc. T.K. has received research grants from GlaxoSmithKline . A.T. is an employee of Eisai Inc. J.C. has served on a speaker's bureau and has received honoraria and research grants from Ariad , Bristol-Myers Squibb , Chemgenex , and Novartis . F.R. has served as a remunerated consultant for Sunesis and Genzyme, has received honoraria from Bristol-Myers Squibb, Celgene, Genzyme, Novartis, and Sunesis, and has received research grants from Bristol-Myers Squibb, Bayer-Onyx, Celgene, EMD Serono, Incyte, Merck, Serono, and Sanofi. All other authors have stated that they have no conflicts of interest.

PY - 2013/10

Y1 - 2013/10

N2 - Background: After the World Health Organization (WHO) changed the definition of acute myeloid leukemia (AML) to ≥ 20% blasts, the International Working Group (IWG) response criteria for myelodysplasia were updated. This retrospective analysis evaluated response to decitabine using updated IWG criteria in patients pooled from 2 decitabine trials. Patients and Methods: Outcomes for patients with myelodysplastic syndrome (MDS) with baseline marrow blasts ≥ 20% and < 30% (RAEB-t group) and < 20% (MDS group) were compared. Results: Patients with RAEB-t (n = 26) had a significantly shorter time from diagnosis to study treatment (7.3 vs. 18.3 months), a higher International Prognostic Scoring System (IPSS) risk (77% vs. 16% high-risk patients), and lower median baseline platelet count (62.3 vs. 112.7 × 103/μL) vs. patients with MDS (n = 157), yet no significant difference in overall response rate (ORR) (15.4% vs. 28.0%). Patients with MDS had better duration of response (9.9 vs. 5 months; P =.024) and overall survival (OS) (16.6 vs. 9.0 months; P =.021) compared with patients with RAEB-t. Conclusion: Decitabine is active in and may benefit patients with > 20% blasts (RAEB-t).

AB - Background: After the World Health Organization (WHO) changed the definition of acute myeloid leukemia (AML) to ≥ 20% blasts, the International Working Group (IWG) response criteria for myelodysplasia were updated. This retrospective analysis evaluated response to decitabine using updated IWG criteria in patients pooled from 2 decitabine trials. Patients and Methods: Outcomes for patients with myelodysplastic syndrome (MDS) with baseline marrow blasts ≥ 20% and < 30% (RAEB-t group) and < 20% (MDS group) were compared. Results: Patients with RAEB-t (n = 26) had a significantly shorter time from diagnosis to study treatment (7.3 vs. 18.3 months), a higher International Prognostic Scoring System (IPSS) risk (77% vs. 16% high-risk patients), and lower median baseline platelet count (62.3 vs. 112.7 × 103/μL) vs. patients with MDS (n = 157), yet no significant difference in overall response rate (ORR) (15.4% vs. 28.0%). Patients with MDS had better duration of response (9.9 vs. 5 months; P =.024) and overall survival (OS) (16.6 vs. 9.0 months; P =.021) compared with patients with RAEB-t. Conclusion: Decitabine is active in and may benefit patients with > 20% blasts (RAEB-t).

KW - Acute myeloid leukemia

KW - FAB classification

KW - Myelodysplastic syndrome

KW - RAEB-t

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84884131596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884131596&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2013.05.004

DO - 10.1016/j.clml.2013.05.004

M3 - Article

C2 - 23790798

AN - SCOPUS:84884131596

SN - 2152-2650

VL - 13

SP - 592

EP - 596

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

IS - 5

ER -

Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this